Kemal Rajabally - Financial Director

Kemal Rajabally is the Finance Director at Richmond Pharmacology, where he oversees the company's financial strategy and operations, ensuring robust financial health and compliance. Kemal plays a critical role in managing Richmond's financial planning, budgeting, and risk management. His strategic oversight extends to the efficient handling and security of the company’s vast data assets, which are crucial for the integrity and success of clinical trials.

With over 30 years of experience in finance, Kemal has developed a strong expertise in financial and commercial management, having held various senior positions in different industries. At Richmond, he has been instrumental in implementing advanced financial systems and processes that enhance the company’s operational efficiency and data security. His efforts have included the introduction of real-time location tracking systems for managing clinical trial data, significantly improving the efficiency and security of patient data management​​.

Under his leadership, the finance team ensures accurate financial reporting, effective budget management, and compliance with regulatory requirements. Kemal’s commitment to excellence and efficiency aligns perfectly with Richmond’s core values, driving the company’s financial strategy towards sustainable growth and success.

Connect with Kemal on LinkedIn - Kemal Rajabally's LinkedIn.

Back to experts

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event